CSafe Global launches real-time shipment visibility platform
Industry customers now have access to 24/7 real-time shipment visibility across the company's entire product portfolio
CSafe Global, an innovation provider of temperature-controlled container solutions for pharmaceuticals transformation has announced the full commercial launch of its real-time shipment visibility platform and technology.
Users of CSafe can now make data-driven decisions to ensure the safe delivery of medicines to patients worldwide.
Available now to CSafe air cargo customers, the company has already started retrofitting active RKN and RAP containers with the new sensors capable of tracking location and condition.
The platform, custom built by Cloudleaf in close collaboration with CSafe operations, provides real-time alerts and notifications directly to customers via email, text or in the platform itself of the following for each shipment: cargo temperature outside set parameters, door open events, ambient temperature change outside set parameters, shock event, tilt event, ambient pressure change outside set parameters, ambient humidity change outside set parameters and route deviation/delay.
The new platform will also benefit customers with its range of other additional features; for example, they will have access to historical shipments, be able to add unlimited platform users and receive GDP-compliant standard shipment reports.
Describing the culmination of the 2-year project, Patrick Schafer, CSafe CEO, said the new platform delivers "so much more than just basic functionality". Instead, it is a "system that is fit for our customers’ needs today and agile enough to easily accommodate enhancements and new innovations well into the future," he added.
The work is not yet over. Tom Weir, CSafe COO, said the company will be retrofitting the remainder of the active container fleet throughout Q1 before moving on to enhancements. The company also plans to bring its cell & gene customers onto the platform and implement the system for VIP Parcel containers and customers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.